Education
About Us
Working with TipRanks
Follow Us
Delcath Systems (DCTH)
NASDAQ:DCTH
DCTH Stock Chart & Stats
Day’s Range― - ―
52-Week Range$8.08 - $18.23
Previous CloseN/A
Volume96.76K
Average Volume (3M)702.88K
Market Cap
$373.25M
Enterprise Value$467.56M
Total Cash (Recent Filing)$81.00M
Total Debt (Recent Filing)$993.00K
Price to Earnings (P/E)234.5
Beta1.48
Next Earnings
Nov 11, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.07
Shares Outstanding34,981,255
10 Day Avg. Volume483,516
30 Day Avg. Volume702,884
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.25
Enterprise Value/Revenue6.82
Enterprise Value/Gross Profit7.75
Enterprise Value/Ebitda35.13
Forecast
1Y Price Target
$26.33Price Target Upside135.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
Bulls Say, Bears Say
Bulls Say
Market OpportunityDelcath estimates a combined $1.0B market opportunity for Hepzato in liver metastases due to colorectal and breast cancer, an attractive long-term growth opportunity.
Revenue GrowthHepzato and Chemosat revenue beat consensus, signaling continued growth.
Study ResultsWe see upside potential on a positive readout from the CHOPIN study - most investors are only focused on the price discount for 340b.
Bears Say
Pricing ImpactDelcath expects a ~10-15% discount per Hepzato kit regarding 340b.
Revenue GuidanceManagement modestly lowered 2025 revenue guidance to $93M-$96M, from prior $94M-$98M.
Site ActivationDelcath lowered expected site activation in 2025, but the change is not seen as material.
Delcath Systems News
DCTH FAQ
What was Delcath Systems’s price range in the past 12 months?
Delcath Systems lowest stock price was $8.08 and its highest was $18.23 in the past 12 months.
What is Delcath Systems’s market cap?
Delcath Systems’s market cap is $373.25M.
When is Delcath Systems’s upcoming earnings report date?
Delcath Systems’s upcoming earnings report date is Nov 11, 2025 which is in 54 days.
How were Delcath Systems’s earnings last quarter?
Delcath Systems released its earnings results on Aug 06, 2025. The company reported $0.07 earnings per share for the quarter, beating the consensus estimate of $0.027 by $0.043.
Is Delcath Systems overvalued?
According to Wall Street analysts Delcath Systems’s price is currently Undervalued.
Does Delcath Systems pay dividends?
Delcath Systems does not currently pay dividends.
What is Delcath Systems’s EPS estimate?
Delcath Systems’s EPS estimate is -0.04.
How many shares outstanding does Delcath Systems have?
Delcath Systems has 34,981,255 shares outstanding.
What happened to Delcath Systems’s price movement after its last earnings report?
Delcath Systems reported an EPS of $0.07 in its last earnings report, beating expectations of $0.027. Following the earnings report the stock price went up 1.141%.
Which hedge fund is a major shareholder of Delcath Systems?
Currently, no hedge funds are holding shares in DCTH
Delcath Systems Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$26.33 (135.09% Upside)
$26.33 (135.09% Upside)
Blogger Sentiment
Bullish
DCTH Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Decreased
By 983.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.2%
Last 30 Days ▼ 11.2%
Last 30 Days ▼ 11.2%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
16.00%
12-Months-Change
Fundamentals
Return on Equity
4.09%
Trailing 12-Months
Asset Growth
244.63%
Trailing 12-Months
Company Description
Delcath Systems
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.
DCTH Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call highlighted the company's strong revenue growth and positive financial performance, along with strategic expansions and future trial prospects. However, the call also noted challenges in site activations, revenue guidance adjustments, and increased R&D expenses. The participation in the 340B program presents both opportunities and challenges.View all DCTH earnings summariesDCTH Stock 12 Month Forecast
Average Price Target
$26.33
▲(135.09% Upside)
Technical Analysis
SurModics
―
ClearPoint Neuro
―
Senseonics Holdings
―
Nano-X Imaging
―
Treace Medical Concepts
―
Ownership Overview
31.14% Insiders
5.24% Mutual Funds
23.24% Other Institutional Investors
30.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---